抗核抗体产生与类风湿关节炎生物制剂治疗反应不佳相关
该研究基于日本单中心队列,纳入接受或未接受bDMARDs的RA患者(n=657和n=211),发现bDMARDs启动后3个月和6-12个月ANA产生(≥2倍基线)分别与3-12个月和12-24个月治疗反应不足显著相关(OR=3.51,p=0.020;OR=3.16,p=0.038)。IFX使用是ANA产生的风险因素(OR=6.24,p<0.001),非TNFi bDMARDs与ANA产生无关。
要点
- bDMARDs治疗后ANA产生与治疗反应不足显著相关
- IFX使用是ANA产生的风险因素,其他TNFi呈相同趋势
- 非TNFi bDMARDs与ANA产生无关
核心结论
- ANA产生可能是RA患者接受bDMARDs治疗反应不佳的标志物。
- 未定义的因素可能影响ANA产生及后续bDMARDs治疗结局。
研究设计与样本
- 日本单中心队列研究,纳入接受bDMARDs(n=657)或未接受bDMARDs(n=211)作为一线bDMARD的RA患者。
- 采用间接免疫荧光法在多个治疗时间点检测ANA。
- 分析ANA产生与治疗反应不足的关联,并分析ANA产生的相关因素。
主要发现
- bDMARDs启动后3个月ANA产生(≥2倍基线)与3-12个月治疗反应不足显著相关(OR=3.51,p=0.020)。
- bDMARDs启动后6-12个月ANA产生与12-24个月治疗反应不足显著相关(OR=3.16,p=0.038)。
- 条件于每种bDMARD使用后关联仍显著。
- IFX使用是ANA产生的风险因素(OR=6.24,p<0.001),其他TNFi呈相同趋势。
- 非TNFi bDMARDs与ANA产生无关。
关键数值与推荐
- ANA产生定义为≥2倍基线水平。
- 治疗反应不足的评估时间点为3-12个月和12-24个月。
临床怎么用
- 在RA患者接受bDMARDs治疗期间,监测ANA产生可能有助于识别治疗反应不佳风险较高的患者。
局限性
- 未定义的因素可能影响ANA产生及后续bDMARDs治疗结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It has been well known that TNF-α inhibitor (TNFi) treatment for patients with rheumatoid arthritis (RA) is associated with anti-nuclear antibody (ANA) development. We previously reported that ANA development was associated with poor outcomes of infliximab (IFX) treatment (1). However, no replication studies have been reported to date. In addition, whether the findings are true to general biological disease-modifying anti-rheumatic drugs (bDMARDs) is uncertain. METHODS: To evaluate an association between treatment response and ANA development during bDMARDs treatment in RA and to analyze correlates of ANA development, Japanese RA patients treated with (n = 657) or without (n = 211) bDMARDs as a first line bDMARD were enrolled from a single center cohort. ANA was measured by an indirect immunofluorescence assay at multiple time points of treatment. We analyzed associations between ANA development and insufficient response to treatment. Correlates of ANA development were also analyzed. RESULTS: ANA development (≥2 times baseline levels) at 3 months and at 6-12 months after bDMARDs initiation were significantly associated with insufficient response at 3-12 months (odds ratio (OR)=3.51, p = 0.020) and at 12-24 months (OR = 3.16, p = 0.038), respectively. The associations remained significant after conditioning on the use of each bDMARD. The use of IFX (OR = 6.24, p < 0.001) was a risk for ANA development, and other TNFi showed the same tends as infliximab. On the other hand, non-TNFi bDMARDs were not associated with ANA development. CONCLUSIONS: ANA development could be a marker of poor treatment response in RA patients undergoing bDMARDs treatment. Undefined factors might influence ANA development and subsequent poor bDMARDs outcome in RA.
引用
- Ishikawa Y, Hashimoto M, Ito H, et al. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019. PMID: 30803720. doi:10.1016/j.semarthrit.2019.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。